Literature DB >> 16061518

Minocycline as a neuroprotective agent.

David P Stirling1, Kaveh M Koochesfahani, John D Steeves, Wolfram Tetzlaff.   

Abstract

Several studies have shown that minocycline, a semisynthetic, second-generation tetracycline derivative, is neuroprotective in animal models of central nervous system trauma and several neurodegenerative diseases. Common to all these reports are the beneficial effects of minocycline in reducing neural inflammation and preventing cell death. Here, the authors review the proposed mechanisms of action of minocycline and suggest that minocycline may inhibit several aspects of the inflammatory response and prevent cell death through the inhibition of the p38 mitogen-activated protein kinase pathway, an important regulator of immune cell function and cell death.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061518     DOI: 10.1177/1073858405275175

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  88 in total

1.  Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition.

Authors:  Tao Pang; Juan Wang; Julius Benicky; Juan M Saavedra
Journal:  Biochim Biophys Acta       Date:  2012-01-27

Review 2.  Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.

Authors:  Gislaine Zilli Réus; Airam Barbosa de Moura; Laura Araújo Borba; Helena Mendes Abelaira; João Quevedo
Journal:  Mol Neuropsychiatry       Date:  2019-05-21

3.  Profile of minocycline neuroprotection in bilirubin-induced auditory system dysfunction.

Authors:  Ann C Rice; Victoria L Chiou; Sarah B Zuckoff; Steven M Shapiro
Journal:  Brain Res       Date:  2010-11-12       Impact factor: 3.252

4.  Minocycline reduced craving for cigarettes but did not affect smoking or intravenous nicotine responses in humans.

Authors:  Mehmet Sofuoglu; Andrew J Waters; Marc Mooney; Stephanie S O'Malley
Journal:  Pharmacol Biochem Behav       Date:  2008-11-13       Impact factor: 3.533

5.  Minocycline improves functional outcomes, memory deficits, and histopathology after endovascular perforation-induced subarachnoid hemorrhage in rats.

Authors:  Prativa Sherchan; Tim Lekic; Hidenori Suzuki; Yu Hasegawa; William Rolland; Kamil Duris; Yan Zhan; Jiping Tang; John H Zhang
Journal:  J Neurotrauma       Date:  2011-10-20       Impact factor: 5.269

Review 6.  p38(MAPK): stress responses from molecular mechanisms to therapeutics.

Authors:  Lydia R Coulthard; Danielle E White; Dominic L Jones; Michael F McDermott; Susan A Burchill
Journal:  Trends Mol Med       Date:  2009-08-06       Impact factor: 11.951

7.  Effect of minocycline on pentylenetetrazol-induced chemical kindled seizures in mice.

Authors:  Nooshin Ahmadirad; Amir Shojaei; Mohammad Javan; Mohammad H Pourgholami; Javad Mirnajafi-Zadeh
Journal:  Neurol Sci       Date:  2013-10-15       Impact factor: 3.307

Review 8.  Intracerebral hemorrhage in mouse models: therapeutic interventions and functional recovery.

Authors:  Balachandar Kathirvelu; S Thomas Carmichael
Journal:  Metab Brain Dis       Date:  2014-05-10       Impact factor: 3.584

Review 9.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.